Key result
An elevated platelet-to-lymphocyte ratio is associated with increased short-term and long-term mortality in heart failure patients, including an adjusted HR of 3.22 for 30-day fatality at a cut-off >272.9.
Why the study?
Platelets and lymphocytes are involved in the relationship between heart failure and systemic inflammation, suggesting the platelet to lymphocyte ratio could be a marker of severity.
Does the platelet to lymphocyte ratio predict mortality in patients with heart failure?
Does the platelet to lymphocyte ratio predict mortality in patients with heart failure?
Hazard Ratio: 3.22 (95% CI 1.56–5.68)
p-value: p=<0.001
An elevated platelet to lymphocyte ratio serves as a prognostic biomarker associated with increased short- and long-term mortality in patients with heart failure.
No takes yet. Share an insight, caveat, or question.
May inform mortality risk stratification in heart failure; leaves open prospective validation and incremental utility.
Delcea et al. (2023) conducted a review in Heart failure (n=17,060). Elevated platelet to lymphocyte ratio (PLR) vs. Lower platelet to lymphocyte ratio was evaluated on 30-day fatality (representative short-term outcome) (HR 3.22, 95% CI 1.56-5.68, p=<0.001). An elevated platelet-to-lymphocyte ratio is associated with increased short-term and long-term mortality in heart failure patients, including an adjusted HR of 3.22 for 30-day fatality at a cut-off >272.9.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: